Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

The Lancet Oncology

Volumn 19, Issue 1, 2018, Pages 40-50

  Denkert, Carsten ^a,b,c   von Minckwitz, Gunter ^d   Darb Esfahani, Silvia ^a,b   Lederer, Bianca ^d   Heppner, Barbara I ^a,b   Weber, Karsten E ^d   Budczies, Jan ^a,b,c   Huober, Jens ^e   Klauschen, Frederick ^a,b   Furlanetto, Jenny ^d   Schmitt, Wolfgang D ^a,b   Blohmer, Jens Uwe ^a   Karn, Thomas ^f   Pfitzner, Berit M ^a,b   Kümmel, Sherko ^g   Engels, Knut ^h   Schneeweiss, Andreas ⁱ   Hartmann, Arndt ^j   Noske, Aurelia ^k   Fasching, Peter A ^l   Jackisch, Christian ^m   van Mackelenbergh, Marion ^d   Sinn, Peter ⁱ   Schem, Christian ⁿ   Hanusch, Claus ^o   Untch, Michael ^p   Loibl, Sibylle ^d   more..

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b BERLIN INSTITUTE OF HEALTH   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d German Breast Group (GBG Forschungs GmbH)   (Germany)

^e UNIVERSITY OF ULM   (Germany)

^f GOETHE UNIVERSITY   (Germany)

^g KLINIKEN ESSEN MITTE   (Germany)

^h Zentrum für Pathologie Zytologie und Molekularpathologie   (Germany)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^k TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^l UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^m SANA KLINIKUM OFFENBACH   (Germany)

ⁿ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^o Rotkreuzklinikum   (Germany)

^p HELIOS KLINIKUM BERLIN BUCH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADJUVANT THERAPY; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; GERMANY; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; LEUKOCYTE COUNT; LUMINAL HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER; NEOADJUVANT CHEMOTHERAPY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROMA CELL; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; ADJUVANT CHEMOTHERAPY; ADULT; BREAST TUMOR; CHEMISTRY; DRUG EFFECT; FEMALE; IMMUNOLOGY; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85039773759     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30904-X     Document Type: Article

References (33)

1. Denkert, C, Loibl, S, Noske, A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28 (2010), 105–113.
2. Savas, P, Salgado, R, Denkert, C, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol 4 (2016), 228–241.
3. Nanda, R, Chow, LQ, Dees, EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 34 (2016), 2460–2467.
4. Adams, S, Diamond, JR, Hamilton, EP, et al. Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). Proc Am Soc Clin Oncol, 34(suppl), 2016 abstr 1009.
5. Cortazar, P, Zhang, L, Untch, M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384 (2014), 164–172.
6. von Minckwitz, G, Raab, G, Caputo, A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23 (2005), 2676–2685.
7. von Minckwitz, G, Blohmer, JU, Costa, SD, et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 31 (2013), 3623–3630.
8. von Minckwitz, G, Rezai, M, Loibl, S, et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 28 (2010), 2015–2023.
9. Untch, M, Loibl, S, Bischoff, J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 13 (2012), 135–144.
10. von Minckwitz, G, Eidtmann, H, Rezai, M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366 (2012), 299–309.
11. von Minckwitz, G, Schneeweiss, A, Loibl, S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 15 (2014), 747–756.
12. Untch, M, Jackisch, C, Schneeweiss, A, et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol 17 (2016), 345–356.
13. Ingold Heppner, B, Untch, M, Denkert, C, et al. Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant-treated HER2-positive breast cancer. Clin Cancer Res 22 (2016), 5747–5754.
14. Issa-Nummer, Y, Darb-Esfahani, S, Loibl, S, et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer—a substudy of the neoadjuvant GeparQuinto trial. PLoS One, 8, 2013, e79775.
15. Denkert, C, von Minckwitz, G, Brase, JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 33 (2015), 983–991.
16. McShane, LM, Altman, DG, Sauerbrei, W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97 (2005), 1180–1184.
17. Salgado, R, Denkert, C, Demaria, S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26 (2015), 259–271.
18. Curtis, C, Shah, SP, Chin, SF, et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 486 (2012), 346–352.
19. Becht, E, Giraldo, NA, Lacroix, L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol, 17, 2016, 218.
20. Costa, SD, Loibl, S, Kaufmann, M, et al. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. J Clin Oncol 28 (2010), 83–91.
21. Dunbier, AK, Ghazoui, Z, Anderson, H, et al. Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance. Clin Cancer Res 19 (2013), 2775–2786.
22. Gao, Q, Patani, N, Dunbier, AK, et al. Effect of aromatase inhibition on functional gene modules in estrogen receptor-positive breast cancer and their relationship with antiproliferative response. Clin Cancer Res 20 (2014), 2485–2494.
23. Iglesia, MD, Parker, JS, Hoadley, KA, et al. Genomic analysis of immune cell infiltrates across 11 tumor types. J Natl Cancer Inst, 108, 2016, djw144.
24. Rooney, MS, Shukla, SA, Wu, CJ, et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160 (2015), 48–61.
25. Iglesia, MD, Vincent, BG, Parker, JS, et al. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res 20 (2014), 3818–3829.
26. Bianchini, G, Qi, Y, Alvarez, RH, et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol 28 (2010), 4316–4323.
27. Rody, A, Holtrich, U, Pusztai, L, et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res, 11, 2009, R15.
28. Newman, AM, Liu, CL, Green, MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12 (2015), 453–457.
29. Gentles, AJ, Newman, AM, Liu, CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 21 (2015), 938–945.
30. Bense, RD, Sotiriou, C, Piccart-Gebhart, MJ, et al. Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer. J Natl Cancer Inst, 109, 2016, djw192.
31. Ali, HR, Chlon, L, Pharoah, PD, Markowetz, F, Caldas, C, Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study. PLoS Med, 13, 2016, e1002194.
32. Smid, M, Rodríguez-González, FG, Sieuwerts, AM, et al. Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nat Commun, 7, 2016, 12910.
33. Lehmann, BD, Jovanović B, Chen, X, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One, 11, 2016, e0157368.